REG - EKF Diagnostics Hldg - AGM Statement

EKF Diagnostics HoldingsAnnouncement

20/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250520:nRST3030Ja&default-theme=true

RNS Number : 3030J  EKF Diagnostics Holdings PLC  20 May 2025

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

AGM Statement

& Positive Q1 Trading update

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, provides an update to shareholders ahead of its Annual General
Meeting ('AGM') today at Harwood Capital LLP, 6 Stratton Street, Mayfair,
London W1J 8LD at 11.00 am.

 

The Company is providing a facility for shareholders to listen in to the AGM,
either online or telephonically (in a non-voting capacity), and there will be
an opportunity for shareholders to ask questions. For dial-in details and to
submit any questions please contact Walbrook PR via email
at ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)  or call +44 (0)20 7933
8780.

 

Executive Chair's AGM statement

I am delighted to announce that trading in the early part of the year ended 31
December 2025 ("FY 2025") is in-line with management expectations.

 

Last year we concluded our rationalisation process and in the new financial
year we are experiencing the benefits of a more simplified business with
greater commercial focus on higher margin products and services. As a result
adjusted EBITDA(1) performance has held up well, against the head winds of
tariffs and unfavourable exchange rates in the US.

 

The implementation of our five-year strategic development has begun in earnest
and as we recently announced, the key area of growth within our point-of-care
division is Hematology. We continue to exploit our no. 2 position in
Hemoglobin point-of-care testing and we currently have a strong order book,
particularly for analysers across Latin America.

 

Within our Life Sciences division sales of β-HB remain robust and our
pipeline for contract manufacturing and fermentation opportunities has
significantly improved with a number of high value prospects currently in
discussions.

 

Cash generation continues to be very strong even with the planned investment
for growth that we have incorporated into our five-year plan, as well as the
use of surplus cash to undertake a successful £1m share buyback programme.
Cash as of 9 May is at £15.7m and we continue to expect cash to finish the
year significantly higher than FY 2024 levels.

 

We are very excited about the prospects of the business and we remain on track
to deliver growth at the revenue and adjusted EBITDA levels for FY 2025
in-line with market expectations.

 

(1)adjusted earnings before interest, tax, depreciation and amortisation,
share-based payments and exceptional items

 

 

 EKF Diagnostics Holdings plc                                 www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair / Stephen Young, CFO           via Walbrook PR

 Singer Capital Markets (Nominated Adviser & Broker)                                        Tel: +44 (0)20 7496 3000
 Phil Davies / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMSFLESUEISEEI